The Efficacy of Sequential RT After Triple Therapy for uHCC

The Efficacy of Sequential Radiotherapy After the Combination of Transcatheter Arterial Chemoembolization With Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma

Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.

Inclusion Criteria:

• Patients diagnosed with HCC and assessed as unresectable by multidisciplinary team (MDT)
• Patients who achieved PR or SD after triple therapy according to the mRECIST and did not meet the criteria for radical surgical resection or could not tolerate surgical treatment
• Patients who received sequential radiotherapy
• Age between 18 and 75 years
• Child-Pugh class A or B
• Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1

Exclusion Criteria:

• Previous acceptance of other antitumor treatments
• Treatment in conjunction with other treatment regimens, such as radiofrequency ablation and chemotherapy
• History of other malignancies
• Incomplete data.